Allogene Therapeutics, Inc. (ALLO) News

Allogene Therapeutics, Inc. (ALLO): $2.55

0.11 (+4.51%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Filter ALLO News Items

ALLO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALLO News Highlights

  • For ALLO, its 30 day story count is now at 4.
  • Over the past 19 days, the trend for ALLO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ALLO are DEC and TOP.

Latest ALLO News From Around the Web

Below are the latest news stories about ALLOGENE THERAPEUTICS INC that investors may wish to consider to help them evaluate ALLO as an investment opportunity.

The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics

Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | December 28, 2023

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.

Yahoo | December 27, 2023

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

Yahoo | December 21, 2023

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

Comprehensive Review of All Patients in the Phase 1 ALPHA/ALPHA2 Trials Demonstrate that Adding Investigational ALLO-647 to Standard Lymphodepletion Can Yield Durable Responses and a Safety Profile Comparable to Approved Autologous CAR T TherapiesCompany Received Fast Track Designation for ALLO-647 for Use in Adult Patients with Relapsed/Refractory Large B-Cell Lymphoma in November 2023 SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a c

Yahoo | December 9, 2023

Allogene Therapeutics Announces Participation in December Investor Conference

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in one upcoming investor conference in December. The JMP Securities Hematology and Oncology SummitWednesday, December 6, 20238:30AM PT/11:30AM ET Any available webcasts will be posted to the Company's website at www.allogene.com und

Yahoo | December 1, 2023

7 Penny Stocks With Low Floats and High Short Interest

Is the 'smart money' on the money shorting these low-float penny stocks, or is there the opportunity for a short squeeze?

Thomas Niel on InvestorPlace | November 24, 2023

Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know

Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | November 10, 2023

Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues

Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.

Yahoo | November 8, 2023

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript November 2, 2023 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.37, expectations were $-0.53. Operator: Hello, and thank you for standing by. Welcome to the Allogene Therapeutics Third Quarter 2023 Conference Call. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] […]

Yahoo | November 3, 2023

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

Research Provides Early Validation of ALLO-182, an AlloCAR T™ Candidate in the IND-Enabling Phase of Development Targeting Claudin18.2 for the Treatment of Patients with Gastric and Pancreatic Cancers SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented preclinical data on a novel off-the-shelf AlloCAR T prod

Yahoo | November 3, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!